Results 101 to 110 of about 422,013 (303)

IMI - Interventions for Controlling Myopia Onset and Progression 2025 [PDF]

open access: yes
Myopia is recognized as a significant public health problem, particularly in East and Southeast Asia. This has led to the development and evaluation of a range of interventions to slow its progression and delay its onset.
Read, Scott A   +43 more
core   +1 more source

Role of aquaporin 1 signalling in cancer development and progression [PDF]

open access: yes, 2017
Published: 29 January 2017Cancer is a major health burden worldwide. Despite the advances in our understanding of its pathogenesis and continued improvement in cancer management and outcomes, there remains a strong clinical demand for more accurate and ...
Eric Smith   +13 more
core   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

open access: yesMolecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou   +12 more
wiley   +1 more source

Risk factors for scoliosis progression in children with idiopathic short stature on growth hormone therapy

open access: yesJournal of Orthopaedic Surgery and Research
Objective To analyze the clinical characteristics of scoliosis in children with idiopathic short stature after growth hormone treatment, and to explore the influence of growth hormone treatment on the progression of scoliosis and the risk factors for the
Xinkai Zhang   +5 more
doaj   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Impacts of continued progression on the longitudinal construction of geographic reasoning in elementary school

open access: yes, 2022
Based on research carried out with elementary school students in the state of São Paulo, this paper seeks to highlight the problem behind the system of Cycles and Continuous Progression for the effective construction of basic knowledge for geographic ...
Souza, André Caetano
core  

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

open access: yesMolecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski   +10 more
wiley   +1 more source

Continued progression as a factor of social and cognitive development of the intellectual handicapped student

open access: yes, 2014
Trata-se de uma pesquisa empírica de abordagem qualitativa, que visa compreender se o sistema educacional em ciclos de progressão contribui de maneira positiva para o desenvolvimento social e cognitivo de alunos com deficiência Intelectual.
Simões, Marisa Ramos Pereira
core  

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON

open access: yesRMD Open
Objective We assessed adverse events and changes in forced vital capacity (FVC) in patients treated with open-label nintedanib over 148 weeks of SENSCIS-ON, the extension of the SENSCIS trial.Methods Adverse events and changes in FVC over 148 weeks of ...
Yannick Allanore   +9 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy